← Back to All US Stocks

MLSS Stock Analysis 2026 - MILESTONE SCIENTIFIC INC. AI Rating

MLSS NYSE Orthopedic, Prosthetic & Surgical Appliances & Supplies DE CIK: 0000855683
Recently Updated • Analysis: Apr 2, 2026 • SEC Data: 2025-12-31
STRONG SELL
92% Conf
Pending
Analysis scheduled

📊 MLSS Key Takeaways

Revenue: $9.0M
Net Margin: -63.8%
Free Cash Flow: $-2.9M
Current Ratio: 1.81x
Debt/Equity: 0.00x
EPS: $-0.07
AI Rating: STRONG SELL with 92% confidence

Is MLSS a Good Investment? Thesis Analysis

Claude

Milestone Scientific is in severe financial distress with persistent operating losses, negative cash flow, and deteriorating profitability despite modest revenue growth. The company is burning cash at an unsustainable rate (-$2.9M operating cash flow on $9M revenue) with no clear path to profitability.

Why Buy MLSS? Key Strengths

Claude
  • + Exceptional gross margin of 71.4% indicates strong product pricing power and cost of goods sold efficiency
  • + Adequate current ratio of 1.81x suggests near-term liquidity is manageable
  • + Revenue growth of 4% YoY demonstrates maintaining customer base despite operational challenges

MLSS Investment Risks to Consider

Claude
  • ! Operating cash flow of -$2.9M annually is unsustainable; company burning 32% of revenue as free cash flow
  • ! Severe operating losses (-$5.7M, -63.5% margin) indicate fundamental operational dysfunction beyond normal scaling phase
  • ! Net income declining 21.4% YoY while revenue grows only 4% shows profitability deteriorating sharply; negative ROE of -203.4% destroys shareholder value
  • ! With only $1.1M cash and -$2.9M annual operating burn, liquidity crisis likely within 12-18 months without intervention
  • ! Zero insider buying activity over 90 days combined with financial distress suggests lack of confidence from management

Key Metrics to Watch

Claude
  • * Operating cash flow trend - critical survival metric; needs positive inflection immediately
  • * Quarterly operating income - must show path to breakeven within 2-3 quarters
  • * Cash balance depletion rate - with current burn, runway is finite
  • * Gross margin sustainability - only bright spot; erosion would accelerate failure
  • * Revenue growth acceleration - 4% is insufficient to absorb fixed operating expenses

MLSS Financial Metrics

Revenue
$9.0M
Net Income
$-5.7M
EPS (Diluted)
$-0.07
Free Cash Flow
$-2.9M
Total Assets
$7.8M
Cash Position
$1.1M

💡 AI Analyst Insight

MILESTONE SCIENTIFIC INC. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

MLSS Profitability Ratios

Gross Margin 71.4%
Operating Margin -63.5%
Net Margin -63.8%
ROE -203.4%
ROA -73.3%
FCF Margin -32.7%

MLSS vs Default Sector

How MILESTONE SCIENTIFIC INC. compares to Default sector averages

Net Margin
MLSS -63.8%
vs
Sector Avg 12.0%
MLSS Sector
ROE
MLSS -203.4%
vs
Sector Avg 15.0%
MLSS Sector
Current Ratio
MLSS 1.8x
vs
Sector Avg 1.8x
MLSS Sector
Debt/Equity
MLSS 0.0x
vs
Sector Avg 0.7x
MLSS Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is MLSS Overvalued or Undervalued?

Based on fundamental analysis, MILESTONE SCIENTIFIC INC. has mixed fundamental signals relative to the Default sector in 2026.

Return on Equity
-203.4%
Sector avg: 15%
Net Profit Margin
-63.8%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

MLSS Balance Sheet & Liquidity

Current Ratio
1.81x
Quick Ratio
0.89x
Debt/Equity
0.00x
Debt/Assets
64.0%
Interest Coverage
-2,047.67x
Long-term Debt
N/A

MLSS 5-Year Financial Trend & Growth Analysis

MLSS 5-year financial data: Year 2021: Revenue $10.3M, Net Income -$7.3M, EPS $-0.12. Year 2022: Revenue $10.3M, Net Income -$6.8M, EPS N/A. Year 2023: Revenue $9.8M, Net Income -$8.7M, EPS N/A. Year 2024: Revenue $9.8M, Net Income -$6.9M, EPS N/A. Year 2025: Revenue $9.0M, Net Income -$4.7M, EPS $-0.06.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: MILESTONE SCIENTIFIC INC.'s revenue has declined by 13% over the 5-year period, indicating business contraction. The most recent EPS of $-0.06 indicates the company is currently unprofitable.

MLSS Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-32.7%
Free cash flow / Revenue

MLSS Quarterly Performance

Quarterly financial performance data for MILESTONE SCIENTIFIC INC. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $2.4M $223.6K $-0.01
Q2 2025 $1.9M N/A N/A
Q1 2025 $2.2M N/A N/A
Q3 2024 $2.1M -$1.5M N/A
Q2 2024 $1.9M $223.6K N/A
Q1 2024 $2.2M -$1.3M N/A
Q3 2023 $2.1M -$1.5M N/A
Q2 2023 $1.6M -$2.2M N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

MLSS Capital Allocation

Operating Cash Flow
-$2.9M
Cash generated from operations
Capital Expenditures
$15.1K
Investment in assets
Dividends
None
No dividend program

MLSS SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for MILESTONE SCIENTIFIC INC. (CIK: 0000855683)

📋 Recent SEC Filings

Date Form Document Action
Mar 31, 2026 10-K form10-k.htm View →
Mar 11, 2026 8-K form8-k.htm View →
Jan 20, 2026 8-K form8-k.htm View →
Dec 23, 2025 8-K form8-k.htm View →
Nov 13, 2025 8-K form8-k.htm View →

Frequently Asked Questions about MLSS

What is the AI rating for MLSS?

MILESTONE SCIENTIFIC INC. (MLSS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.

What are MLSS's key strengths?

Claude: Exceptional gross margin of 71.4% indicates strong product pricing power and cost of goods sold efficiency. Adequate current ratio of 1.81x suggests near-term liquidity is manageable.

What are the risks of investing in MLSS?

Claude: Operating cash flow of -$2.9M annually is unsustainable; company burning 32% of revenue as free cash flow. Severe operating losses (-$5.7M, -63.5% margin) indicate fundamental operational dysfunction beyond normal scaling phase.

What is MLSS's revenue and growth?

MILESTONE SCIENTIFIC INC. reported revenue of $9.0M.

Does MLSS pay dividends?

MILESTONE SCIENTIFIC INC. does not currently pay dividends.

Where can I find MLSS SEC filings?

Official SEC filings for MILESTONE SCIENTIFIC INC. (CIK: 0000855683) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is MLSS's EPS?

MILESTONE SCIENTIFIC INC. has a diluted EPS of $-0.07.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is MLSS a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, MILESTONE SCIENTIFIC INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is MLSS stock overvalued or undervalued?

Valuation metrics for MLSS: ROE of -203.4% (sector avg: 15%), net margin of -63.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy MLSS stock in 2026?

Our dual AI analysis gives MILESTONE SCIENTIFIC INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is MLSS's free cash flow?

MILESTONE SCIENTIFIC INC.'s operating cash flow is $-2.9M, with capital expenditures of $15.1K. FCF margin is -32.7%.

How does MLSS compare to other Default stocks?

Vs Default sector averages: Net margin -63.8% (avg: 12%), ROE -203.4% (avg: 15%), current ratio 1.81 (avg: 1.8).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 2, 2026 | Data as of: 2025-12-31 | Powered by Claude AI